NCT07570719 · RECRUITING
Community-based Screening for Alzheimer's Disease
This observational study is testing whether two blood-based biomarkers, a ratio of phosphorylated tau 217 to amyloid beta 42 and a protein called GFAP, can reliably screen for Alzheimer's disease in everyday community settings among older Chinese adults. There is no drug or treatment involved. It is an observational study, meaning researchers are watching and measuring, not intervening. Details beyond the screening focus are limited.
You may qualify if
- Aged 60-80 years
- Capable of normal communication and able to complete the questionnaire
You're excluded if
- Severe mental disorders
- Severe visual, auditory, comprehension or mobility impairments
- Current participation in other health intervention clinical studies
- Severe renal insufficiency, heart failure, cerebrovascular disease, anemia, hyperthyroidism, hypothyroidism
- Multiple cerebral infarctions, severe white matter hyperintensities, history of cerebral hemorrhage, current anticoagulant use, MRI abnormalities (cortical iron deposition, cerebral contusion)
- Unable to comply with study procedures with no legal guardian
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-05-06